Clinical trials

This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients. This study consists of two parts: dose escalation (Part 1) and dose expansion (Part 2). Following a screening period, eligible mAPMR patients will be enrolled to receive their assigned regimen of KMV002 (a combination of SN3001C and CpG ODN adjuvant). KMV002 will be given as either a 5-dose or 6-dose regimen.

This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.